---
title: "Changchun High-Tech Industries (Group) Inc. (000661.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/000661.SZ.md"
symbol: "000661.SZ"
name: "Changchun High-Tech Industries (Group) Inc."
industry: "Pharmaceuticals"
---

# Changchun High-Tech Industries (Group) Inc. (000661.SZ)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | CN Market |
| Website | [ccht.jl.cn](https://ccht.jl.cn) |

## Company Profile

Changchun High-Tech Industry (Group) Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines products in China. The company offers genetic engineering, biological vaccines, antibody drugs, chemical drugs, and moder...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.47)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 75 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -9.72% |  |
| Net Profit YoY | -74.14% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.55 |  |
| Dividend Ratio | 2.93% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 35.65B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 12.88B |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.17% | C |
| Profit Margin | 7.44% | B |
| Gross Margin | 85.61% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -9.72% | D |
| Net Profit YoY | -74.14% | E |
| Total Assets YoY | 1.24% | C |
| Net Assets YoY | -0.30% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1343.44% | B |
| OCF YoY | -9.72% | D |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.41 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 17.55% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Changchun High-Tech Industries (Group) Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.17%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "7.44%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "85.61%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-9.72%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-74.14%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.24%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.30%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1343.44%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-9.72%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.41",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "17.55%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Allist (SH.688578) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (SZ.300573) | A | A | A | B | B | A |
| 03 | Hengrui Pharma (SH.600276) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (SZ.000538) | B | C | B | B | C | B |
| 05 | Salubris (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 37.17 | 88/222 | 40.52 | 20.18 | 17.22 |
| PB | 1.55 | 36/222 | 1.88 | 1.77 | 1.69 |
| PS (TTM) | 2.77 | 56/222 | 3.34 | 3.13 | 2.86 |
| Dividend Yield | 2.93% | 22/222 | 2.93% | 2.56% | 2.21% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-17T16:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 86% |
| Overweight | 1 | 14% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 87.38 |
| Highest Target | 156.00 |
| Lowest Target | 144.48 |

## References

- [Company Overview](https://longbridge.com/en/quote/000661.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/000661.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/000661.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.